Bristol Myers Squibb Presents New Clinical Trial And Real-World Data For Camzyos At ACC Annual Scientific Session & Expo

Positive Phase 3 results of SCOUT-HCM trial highlight potential of Camzyos to be the first cardiac myosin inhibitor for the treatment of adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)

New real-world evidence further reinforces the long-term, consistent efficacy and safety profile of Camzyos across diverse patient populations in oHCM

Bristol Myers Squibb (NYSE:BMY) today announced the presentation of new clinical trial and real-world data for Camzyos (mavacamten) at the American College of Cardiology's (ACC) Annual Scientific Session & Expo, taking place March 28–30, 2026, in New Orleans, Louisiana. Presentations at ACC will build upon the most comprehensive and mature evidence base in symptomatic obstructive hypertrophic cardiomyopathy (oHCM), further establishing Camzyos as a paradigm-shifting therapy across a range of patient populations. New data include multiple real-world data analyses demonstrating the consistent effectiveness and safety profile of Camzyos in adults, as well as full results from SCOUT-HCM, the first Phase 3 clinical trial evaluating a cardiac myosin inhibitor (CMI) as a potential treatment for adolescents with oHCM.